“Connecting the Dots: Strong Policies Foster Life Saving Innovations”
The virtual Summit will take a deep dive into THBI’s legislative priorities as we approach the 87th Texas Legislative Session. THBI’s members are leading the fight against COVID-19 through research and development, and creating vaccines, therapeutics, diagnostics, and medical devices to help cure, treat and prevent illness. Strong policies foster innovations and are necessary for our industry to end the current pandemic and prevent future outbreaks on viruses and deadly diseases. The Summit will bring together life science experts to lead the discussions on what it takes to bring a product to the market, and what Texas can do to support good policy. The event will also highlight industry leaders who have furthered innovation in Texas with the presentation of the annual Luminary Awards.
SPONSORS & EXPO
Please consider sponsoring this important event and support our advocacy efforts as we prepare for an important legislative session. Now is a critical time for our industry, THBI, and member companies like yours, to have a voice at the Texas Capitol. Our industry is leading the response to COVID-19 with more than 750 therapeutic developments in the pipeline. The importance of strong policies to support life science innovation is more important now than ever and we need support from our members as we head into the most important legislative session in years.
Austin Community College Biotechnology Program
Classes are small at 6 students (as a result of Covid 19) and are taught by highly qualified individuals including individuals from industry. The program is offered at night at EVC campus and during the day at RRC. Both sites are equipped with state of the art equipment. Courses are aligned with the Texas Skill Standards in the Biosciences that were and are validated by industry.
- Cancer Insight’s mission is to discover, develop, test, and bring to market emerging immunotherapies. Under the leadership of its CEO, Dr. George Peoples, MD, Cancer Insight is on the vanguard of developing novel immunotherapies. Cancer Insight is a cutting-edge clinical Contract Research Organization (CRO) that designs and executes immuno–oncology (IO) clinical trials.
Cancer Insight offers a vertical range of CRO services from trial design to final execution, with a foundation grounded on decades of scientific research and clinical trial experience. While providing the comprehensive CRO services needed to execute a clinical trial, Cancer Insight also offers consultation on trial design, regulatory strategy, and clinical development strategy. Cancer Insight is conducting multiple trials in vaccines, personalized IO products, mABs, checkpoint inhibitors, therapeutic proteins, immune-modulators, and combinations of these agents. Cancer Insight has an extensive network of collaborators and subject matter experts, as well as a vast network of study sites at both academic institutions and high volume community practices.
CRB is a global design, construction, and consulting firm that relentlessly pursues and delivers success for our clients in advanced technology industries. CRB was founded in 1984 as a single three-person office and has grown to a team of more than 1,200 passionate professionals in 18 offices throughout the world. We design and build some of the most powerful facilities in the world – those that change people’s lives.
Merck aspires to be the premier research-intensive biopharmaceutical company in the world
We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.
Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These companies’ 1,800 employees in the U.S. develop and commercialize medicines in mental health, oncology, cardio-renal and nephrology, using cutting-edge technology to address unmet healthcare needs. Otsuka’s most recently approved product in the U.S. is indicated for the treatment of adults with schizophrenia and as an adjunctive therapy to antidepressant medications for adults with major depressive disorder. In the medical device field, Otsuka markets a urea breath test used to detect H. pylori infection in the digestive tract.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 6,000 people worldwide and had consolidated sales of approximately USD 11.1 billion in 2017.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at otsuka-us.com. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at otsuka.co.jp/en/.
Learn more about Otsuka here.
Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at Pfizer.com.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio that includes 3 approved therapies and ~20 programs in clinical or pre-clinical development aimed at addressing diseases with high unmet medical need and clear biology, for which there are no approved therapies. Our primary responsibility is to our patients, and we are passionate about educating and supporting patients, families and caregivers affected by rare and ultra-rare diseases.
As a comprehensive health science university, the mission of The University of Texas Health Science Center at Houston is to educate health science professionals, discover and translate advances in the biomedical and social sciences, and model the best practices in clinical care and public health.
We pursue this mission in order to advance the quality of human life by enhancing the diagnosis, treatment, and prevention of disease and injury, as well as promoting individual health and community well-being.
Excellence above all in the quest to be an acknowledged leader in the collaboration to treat, cure and prevent the most common diseases of our time through education, research and clinical practice.
UT Health San Antonio
The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio, is one of the country’s leading health sciences universities, designated as a Hispanic-Serving Institution by the U.S. Department of Education and the premier academic research center in San Antonio and South Texas. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. The UT Health Science Center at San Antonio is ranked in the top 3 percent worldwide for all organizations that receive National Institutes of Health funding. It is the chief catalyst for the $40.2 billion health care and biosciences sector of the San Antonio economy, the city’s largest economic sector. To learn about the many ways “We make lives better®,” visit uthscsa.edu.